{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:24:45Z","timestamp":1794486285871,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jvacx.2020.100066","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T21:03:43Z","timestamp":1588107823000},"page":"100066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Emerging vaccine manufacturers are innovating for the next decade"],"prefix":"10.1016","volume":"5","author":[{"given":"Benoit","family":"Hayman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Pagliusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2020.100066_b0005","unstructured":"World Economic Situation and Prospect. United Nations; 2019. Available at https:\/\/www.un.org\/development\/desa\/dpad\/wp-content\/uploads\/sites\/45\/WESP2019_BOOK-web.pdf [accessed on 07 January 2020]."},{"issue":"3\u20134","key":"10.1016\/j.jvacx.2020.100066_b0010","first-page":"285","article-title":"Developing Country Vaccine Manufacturers Network (DCVMN), 26\u201327 April 2001, Bandung, Indonesia","volume":"20","author":"Poeloengan","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100066_b0015","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2018."},{"key":"10.1016\/j.jvacx.2020.100066_b0020","unstructured":"UNICEF Supply: Annual Report; 2018. Available at https:\/\/www.unicef.org\/media\/56226\/file\/UNICEF%20supply%20annual%20report%202018%20.pdf."},{"key":"10.1016\/j.jvacx.2020.100066_b0025","doi-asserted-by":"crossref","unstructured":"Peck M, Gacic-Dobo M et al. Global Routine Vaccination Coverage; 2018. Morbidity and mortality weekly report (25 October 2019). Available at https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31647786.","DOI":"10.15585\/mmwr.mm6842a1"},{"key":"10.1016\/j.jvacx.2020.100066_b0030","unstructured":"Progress and Challenges with achieving universal immunization coverage. WHO\/UNICEF; 2018. Available at https:\/\/www.who.int\/immunization\/monitoring_surveillance\/who-immuniz.pdf?ua=1."},{"key":"10.1016\/j.jvacx.2020.100066_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2019.03.025","article-title":"Opportuntities for improving access to vaccines in emerging countries through efficient and aligned registration procedures: An industry perspective","author":"Dellepiane","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100066_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2013.11.066","article-title":"Twenty-five years of the WHO vaccines prequalification programme (1987\u20132012): Lessons learned and future perspectives","author":"Dellepiane","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100066_b0045","unstructured":"Impact Assessment of WHO Prequalification and Systems Supporting Activities. External Assessment Report; 2019. Available at https:\/\/www.who.int\/medicines\/news\/2019\/report_Impact-assessment_WHO-PQ-Reg-systems.pdf."},{"key":"10.1016\/j.jvacx.2020.100066_b0050","unstructured":"Jorba J, Diop OM et al. Update on Vaccine-Derived Polioviruses \u2013 Worldwide. PubMed; 2018. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30359342."},{"key":"10.1016\/j.jvacx.2020.100066_b0055","unstructured":"Gavi-GPEI Supply and Procurement Roadmap Inactivated Polio Vaccine (IPV); August 2017. Available at https:\/\/www.gavi.org\/sites\/default\/files\/document\/ipv-roadmap-public-summarypdf.pdf [accessed on 07 January 2020]."},{"key":"10.1016\/j.jvacx.2020.100066_b0060","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biologicals.2016.08.005","article-title":"Development of inactivated poliovirus vaccine from Sabin strains: A progress report","volume":"44","author":"Okayasu","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.jvacx.2020.100066_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2018.05.035","article-title":"Vaccines, inspiring innovation in health","author":"Pagliusi","year":"2018","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.jvacx.2020.100066_b0070","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.vaccine.2017.09.029","article-title":"A randomized, open label trial to evaluate and compare the immunogenicity and safety of a novel liquid hexavalent DTwP-Hib\/Hep B-IPV (EasySix\u2122) to licensed combination vaccines in healthy infants","volume":"36","author":"Mohanty","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100066_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003832","article-title":"Updated global burden of cholera in endemic countries","author":"Ali","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jvacx.2020.100066_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2018.09.026","article-title":"The Euvichol story \u2013 Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships","author":"Odevall","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100066_b0085","series-title":"An investment case for the accelerated introduction of oral cholera vaccines","author":"Levin","year":"2012"},{"key":"10.1016\/j.jvacx.2020.100066_b0090","unstructured":"Global Task Force on Cholera Control. Ending Cholera- A global Roadmap to 2030; 2017. https:\/\/www.who.int\/cholera\/publications\/global-roadmap-summary.pdf?ua=1."},{"key":"10.1016\/j.jvacx.2020.100066_b0095","unstructured":"WHO and United States Centers for Disease Control and Prevention (CDC) press release; December 2019. Available at https:\/\/www.who.int\/news-room\/detail\/05-12-2019-more-than-140-000-die-from-measles-as-cases-surge-worldwide."},{"key":"10.1016\/j.jvacx.2020.100066_b0100","unstructured":"Pentavalent vaccine support. Gavi, The Vaccine Alliance. Available at https:\/\/www.gavi.org\/types-support\/vaccine-support\/pentavalent."},{"key":"10.1016\/j.jvacx.2020.100066_b0105","unstructured":"Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. PubMed; 2003. Available at https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Dodd%20D%5BAuthor%5D&cauthor=true&cauthor_uid=12564784."},{"key":"10.1016\/j.jvacx.2020.100066_b0110","unstructured":"Pentavalent vaccine (DTwP-HepB-Hib): Market & Supply Update. UNICEF Supply Division; May 2017. Available at https:\/\/www.unicef.org\/supply\/reports\/pentavalent-vaccinedtwp-hepb-hib-market-and-supply-update."},{"issue":"Supplement_4","key":"10.1016\/j.jvacx.2020.100066_b0115","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1093\/infdis\/jiz336","article-title":"Status of the Rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018","volume":"220","author":"Bwaka","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jvacx.2020.100066_b0120","unstructured":"Bharat Biotech Press Release (August 26, 2013). Available at https:\/\/www.dcvmn.org\/IMG\/pdf\/typbar_tcv_news_clips_and_press_release.pdf."},{"key":"10.1016\/j.jvacx.2020.100066_b0125","unstructured":"Typbar TCV\u00ae from Bharat Biotech, World\u2019s First Typhoid Conjugate Vaccine Prequalified by WHO. Press Release (January 3, 2018). Available at https:\/\/www.who.int\/medicines\/news\/2017\/Bharat-Biotech-TypbarTCV-WHO-PQ-Press-Release-Global-Final.pdf."},{"key":"10.1016\/j.jvacx.2020.100066_b0130","unstructured":"DCVMN Annual Report 2018. Available at https:\/\/dcvmn.net\/IMG\/pdf\/dcvmn_2018_annual_report_v9_ec_no_objection_received_9th_sept.pdf."},{"key":"10.1016\/j.jvacx.2020.100066_b0135","unstructured":"WHO prequalifies new rotavirus vaccine. News release; 2018. Available at https:\/\/www.who.int\/medicines\/news\/2018\/prequalified_new-rotavirus_vaccine\/en\/."},{"key":"10.1016\/j.jvacx.2020.100066_b0140","unstructured":"How hand, foot and mouth disease is now vaccine\u2014preventable. World Economic Forum; January 13 2016. Available at https:\/\/www.weforum.org\/agenda\/2016\/01\/how-hand-foot-and-mouth-disease-is-now-vaccine-preventable\/."},{"key":"10.1016\/j.jvacx.2020.100066_b0145","unstructured":"Zero by 30: The Global Strategic Plan to Prevent Human Deaths from Dog-Transmitted Rabies by 2030. Available at https:\/\/www.who.int\/rabies\/resources\/9789241513838\/en\/."},{"key":"10.1016\/j.jvacx.2020.100066_b0150","doi-asserted-by":"crossref","first-page":"B176","DOI":"10.1016\/j.vaccine.2012.11.060","article-title":"Developing Countries Vaccine Manufacturers Network: Doing good by making high-quality vaccines affordable for all","volume":"31","author":"Pagliusi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100066_b0155","unstructured":"Dengue vaccine: WHO position paper. September 2018. Available at https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30424888."},{"key":"10.1016\/j.jvacx.2020.100066_b0160","unstructured":"Questions and Answer on Dengue Vaccines. Last updated 20 April 2018. Available at https:\/\/www.who.int\/immunization\/research\/development\/dengue_q_and_a\/en\/."},{"key":"10.1016\/j.jvacx.2020.100066_b0165","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1016\/j.vaccine.2015.09.105","article-title":"Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine","volume":"33","author":"Precioso","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100066_b0170","unstructured":"Butantan Institute and MSD agree to collaborate on dengue vaccine development. Public Release; 12 December 2018. Available at https:\/\/www.eurekalert.org\/pub_releases\/2018-12\/fda-bia121218.php [accessed on 09 January 2020]."},{"key":"10.1016\/j.jvacx.2020.100066_b0175","unstructured":"Scientific Consultation on Zika Virus Vaccine Development. World Health Organization and National Institute of Allergy and Infectious Diseases, National Institutes of Health. Meeting Summary (10\u201311 January 2017). Available at https:\/\/www.who.int\/immunization\/research\/meetings_workshops\/zikv_vaccdev_jan17\/en\/."},{"key":"10.1016\/j.jvacx.2020.100066_b0180","unstructured":"Bharat Biotech\u2019s Zika, Chikungunya vaccines to enter Phase II trials; focus now on private label market. Press Release (11 March 2019). Available at https:\/\/www.moneycontrol.com\/news\/business\/companies\/bharat-biotechs-zika-chikungunya-vaccines-to-enter-phase-ii-trials-focus-now-on-private-label-market-3633391.html."},{"key":"10.1016\/j.jvacx.2020.100066_b0185","unstructured":"Chikungunya Vaccines in the Pipeline. Workshop on Chikungunya vaccines, Delhi, 5\u20136 February 2018. Presentation available at https:\/\/www.who.int\/immunization\/research\/meetings_workshops\/28_Kang_Chikungunya.pdf."},{"key":"10.1016\/j.jvacx.2020.100066_b0190","unstructured":"WHO World Malaria Report 2018. Published November 2018. Available at https:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2018\/report\/en\/."},{"key":"10.1016\/j.jvacx.2020.100066_b0195","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2217\/fvl-2016-0070","article-title":"Simian adenoviruses as vaccine vectors","volume":"9","author":"Morris","year":"2016","journal-title":"Future Virol"},{"key":"10.1016\/j.jvacx.2020.100066_b0200","doi-asserted-by":"crossref","unstructured":"Tiono AB, et al. First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5\u201317 months old infants and children. PLOS One. https:\/\/doi.org\/10.1371\/journal.pone.0208328.","DOI":"10.1371\/journal.pone.0208328"},{"issue":"4","key":"10.1016\/j.jvacx.2020.100066_b0205","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jvacx.2020.100066_b0210","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvacx.2020.100066_b0215","unstructured":"Human Papillomavirus Vaccine: Supply and Demand Update. UNICEF Supply Division; June 2018. Available at https:\/\/www.unicef.org\/supply\/reports\/human-papillomavirus-hpv-vaccine-supply-and-demand-update."},{"key":"10.1016\/j.jvacx.2020.100066_b0220","unstructured":"WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer; 19 May 2018. Available at https:\/\/www.who.int\/reproductivehealth\/call-to-action-elimination-cervical-cancer\/en\/."},{"key":"10.1016\/j.jvacx.2020.100066_b0225","unstructured":"Qiao YL, Wu T, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial. Journal of the National Cancer Institute (11 May 2019). Available at https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31086947."},{"key":"10.1016\/j.jvacx.2020.100066_b0230","unstructured":"Pneumococcal Conjugate Vaccine: Supply and Demand Update. UNICEF Supply Division; December 2018. Available at https:\/\/www.unicef.org\/supply\/reports\/pneumococcal-conjugate-vaccine-pcv-market-update."},{"issue":"4","key":"10.1016\/j.jvacx.2020.100066_b0235","doi-asserted-by":"crossref","first-page":"e1002791","DOI":"10.1371\/journal.pmed.1002791","article-title":"Tuberculosis vaccines: Rising opportunities","volume":"16","author":"Vekemans","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.jvacx.2020.100066_b0240","unstructured":"Understanding the Challenges of Vaccine Development. Vax. Volume 5 (April 2007). Available at https:\/\/www.vaxreport.org\/vax-2-3-april-2004\/834-understanding-vaccine-development."},{"key":"10.1016\/j.jvacx.2020.100066_b0245","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.jvacx.2020.100066_b0250","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1016\/j.vaccine.2017.04.087","article-title":"An updated methodology to review developing country vaccine manufacturer viability","volume":"35","author":"Luter","year":"2017","journal-title":"Vaccine"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136220300139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136220300139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:02:45Z","timestamp":1762912965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136220300139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":50,"alternative-id":["S2590136220300139"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2020.100066","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging vaccine manufacturers are innovating for the next decade","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2020.100066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 DCVMN International. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100066"}}